# Novel Chinese Medicine Formula for Diabetes

Study · id `cardio:ct-nct06978023` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06978023](<https://clinicaltrials.gov/study/NCT06978023>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06978023

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 162 participants.

## Technical summary

Registry record NCT06978023. Randomized; quadruple masking; primary purpose treatment. Start 2025-05 (anticipated); primary completion 2026-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 162 participants (planned count; ClinicalTrials.gov record NCT06978023, source copy `cardio:ctgov-nct06978023-2025-05-18`, retrieved 2026-10-26)
- Planned start: 2025-05 (anticipated) (ClinicalTrials.gov record NCT06978023, source copy `cardio:ctgov-nct06978023-2025-05-18`, retrieved 2026-10-26)
- Primary completion: 2026-10 (anticipated) (ClinicalTrials.gov record NCT06978023, source copy `cardio:ctgov-nct06978023-2025-05-18`, retrieved 2026-10-26)
- Completion: 2027-02 (anticipated) (ClinicalTrials.gov record NCT06978023, source copy `cardio:ctgov-nct06978023-2025-05-18`, retrieved 2026-10-26)
- Countries: Hong Kong SAR China (ClinicalTrials.gov record NCT06978023, source copy `cardio:ctgov-nct06978023-2025-05-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06978023-2025-05-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Novel Chinese Medicine Formula for Diabetes
- Condition: Type 2 Diabetes
- Intervention (Combination product): JM-LD
- Intervention (Combination product): JM-HD
- Intervention (Combination product): Placebo
- Lead sponsor: Chinese University of Hong Kong
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Chinese University of Hong Kong (`cardio:org-chinese-university-of-hong-kong`)

## Provenance

Content hash: ccf7b0581880ea34b9e868b9b4fba4442b5748ad29b01d041c4df6366cc3c4a4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
